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1Universidad Catolica de Honduras Campus San Pedro Sula Pablo, San Pedro Sula, Honduras, 2Hospital Dr. Mario Catarino Rivas, San Pedro Sula, Honduras, 3Hospital Escuela Universitario, Tegucigalpa, 
Honduras, 4Clinica de Servicios de Atencion Integral, Tegucigalpa, Honduras, 5Department of Medicine, Division of Infection, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
Background. Cryptococcal meningitis is a major cause of death among people with human immunodeficiency virus (PWH). 
Cryptococcal antigen (CrAg) testing of asymptomatic patients is an important public health measure to reduce mortality in high-
incidence areas. However, limited data exist on CrAg prevalence in Central America.
Methods. We conducted a prospective cohort study at the 2 largest human immunodeficiency virus (HIV) clinics and hospitals 
in Honduras. Cryptococcal antigen in serum and cerebrospinal fluid was performed in individuals with HIV who had CD4 ≤100 
cells/mm3 between 2017 and 2018. After CrAg testing, individuals were observed for 12 months to assess mortality using adjusted 
Cox proportional hazard models.
Results. A total of 220 PWH were tested for CrAg, 12.7% (n = 28) of which tested positive. Cryptococcal antigen prevalence was 
higher among hospitalized individuals in 40% (n = 10 of 25) of the cases. The proportion (35.8%) of individuals taking antiretroviral 
therapy was significantly (P < .01) lower among those who tested positive for CrAg. Overall mortality among the cohort was 11.4% 
(n = 25 of 220) by 12 months. Cryptococcal antigen-positive cases were at a significantly higher risk of death (adjusted hazard ratio, 
2.69; 95% confidence interval, 1.07–6.84) compared with CrAg-negative participants.
Conclusions. Cryptococcal antigen prevalence in Honduras was high among PWH. Moreover, individuals who tested positive 
for CrAg testing were at a higher risk of death. Systemic CrAg of PWH with a CD4 ≤100 cells/mm3 should be routinely performed 
in Central America.
Keywords.  cryptococcal antigen; Honduras; Latin America; PWH.
Cryptococcal meningitis (CM) remains one of the leading 
causes of death among people with human immunodeficiency 
virus (PWH) worldwide, with as many as 15% of the deaths 
in PWH being attributed to CM [1]. With the development 
of the cryptococcal antigen (CrAg) lateral-flow assay, an in-
expensive point-of-care test, diagnoses are now accessible in 
low-income countries [2–4], allowing clinicians to screen for 
asymptomatic antigenemia. This approach has been proven to 
be cost-effective [5] and to decrease the number of deaths at-
tributed to CM [6].
Despite the availability of screening and diagnostic tools for 
cryptococcal antigenemia in low-income nations, little is known 
about cryptococcal antigenemia and its burden in Central 
American countries. Although recent evidence suggests high 
burden of CM in Latin America, Central America was not rep-
resented, because no studies exist from this region [1]. Efforts 
to address this gap have been mostly undertaken in South 
American countries [7–9] rather than in Central America or the 
Caribbean, where the burden of human immunodeficiency virus 
(HIV) is high [10] and the epidemic is worsening [11]. Honduras 
has recently reported high mortality rates associated with CM in 
individuals with HIV [12]. The burden of this diseases remains 
unknown in Honduras or any other part of Central America. 
The World Health Organization (WHO) recommends screening 
for CrAg in PWH with a CD4 ≤100 cells/mm3 [13].
To address a public health concern associated with cryp-
tococcosis as an opportunistic infection in PWH in Central 
America, and to address the knowledge gap surrounding cryp-
tococcal disease burden, we conducted a prospective cohort 
study to determine CrAg prevalence and outcomes associated 
at the 2 largest clinics serving PWH in Honduras.
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METHODS
Participants
Between April 2017 and December 2018, we conducted a pro-
spective cohort study at 2 outpatient HIV clinics in San Pedro 
Sula and Tegucigalpa, Honduras as well as at the inpatient 
Infectious Disease Units of Hospital “Escuela Universitario” 
and “Mario Catarino Rivas” in both cities. Medical records 
and laboratory reports were used to identify eligible partici-
pants. This study was nested on a URC-Centers for Disease 
Control and Prevention (CDC) mycotic infections surveillance 
on PWH. We included PWH with a CD4 ≤100 cells/mm3 who 
presented to either HIV clinic or the inpatient units during 
the study period regardless of age. Participants were excluded 
if they had a previous diagnosis of cryptococcosis. All partici-
pants who complied with the study criteria and attended either 
the ambulatory clinic or hospitals were approached, and all who 
consented were included in a sequential manner.
Enrollment and Procedures
Using the HIV outpatient clinics records and laboratory reports, 
we were able to identify eligible individuals for CrAg screening. 
At enrollment, clinical and demographic data were collected 
using URC-CDC Cryptococcosis and Histoplasmosis [14] case 
surveillance forms. In addition, a single whole blood sample was 
collected on each participant to test for CrAg using the Lateral 
Flow Assay (IMMY, Norman, OK) in serum. Participants with 
a positive serum CrAg were contacted 24 hours after the test 
was performed in serum and assessed for CM with a lumbar 
puncture (LP) to rule out CM. Individuals who presented with 
clinical findings that suggested central nervous system (CNS) 
compromise such as seizures, headache, and stiffness of neck 
had a cerebrospinal fluid (CSF) CrAg performed only.
Due to the lack of availability of flucytosine in Honduras, 
participants with positive CSF CrAg received therapy with 
0.5 mg/kg amphotericin B deoxycholate and 800 mg of intra-
venous fluconazole daily for 14  days followed by 400  mg of 
oral fluconazole for 8 weeks and 200  mg afterwards. When 
amphotericin B deoxycholate was not available, 1200  mg of 
fluconazole was given daily for 14 days. Individuals who tested 
positive for CrAg in serum and negative in CSF received ambu-
latory therapy with 800 mg of oral fluconazole daily for 2 weeks 
followed by 200 mg daily for an additional 8 weeks [13].
The follow-up period conducted by the research team was 
composed of 4 visits within 12 months, where clinical exami-
nation was performed to assess potential symptoms of crypto-
coccal disease or recurrence for those individuals who tested 
positive for CrAg. Participants with a negative serum CrAg 
underwent routine follow up by their HIV clinic physicians, 
and potential cryptococcal disease after clinical examination 
was reported to the research team. Mortality was confirmed 
during the 12-month follow-up period using national registries 
and hospital registries at both HIV clinics to minimize loss to 
follow up.
Statistical Analysis
For the statistical analysis, the cohort was divided in CrAg-
positive and CrAg-negative groups. Descriptive statistics were 
performed, and P values were calculated using Fisher’s exact 
test, χ 2 test, or Wilcoxon rank-sum test as needed. To gauge risk 
of mortality after 12-month follow up, Cox proportional hazard 
models were used adjusting for age and antiretroviral therapy 
(ART). Data were analyzed using R version 3.6.1 (available at 
https://www.R-project.org/) using the package “survival”.
Patient Consent Statement
The institutional review boards at Universidad Catolica de 
Honduras and Hospital Escuela Universitario approved the re-
search protocol. Written informed consent was obtained from 
PWH 18 years or older and from parents for children <12 years 
old; assent was obtained from children ≥12 years old, as per the 
guidance of the review boards.
RESULTS
Population Baseline Characteristics
We enrolled 195 individuals in the outpatient clinics (screening) 
and 25 at the inpatient infectious diseases’ units in both hos-
pitals (Figure 1). Overall, the median age was 38 years (inter-
quartile range [IQR], 30–46 years), 64.7% (n = 140) were males, 
and 93.6% (n = 206) were from urban areas. The median CD4 
was 46 cells/mm3 (IQR, 25–72 cells/mm3), and 67% (n = 147) 
were receiving ART at the time of antigen testing (Table 1). The 
median duration of time since HIV diagnosis was 21 months 
(IQR, 1–111 months) among the cohort.
Cryptococcal Antigen Prevalence
Of the 220 enrolled, 12.7% (n = 28) of the individuals had a 
positive CrAg in either the CSF or serum. Furthermore, among 
participants who attended the outpatient clinics, 9.2% (n = 18) 
tested positive for CrAg. Forty percent (n = 10) of the partici-
pants who were hospitalized tested positive for CrAg.
Overall, 9.2% (n = 18) of the outpatient participants tested 
positive for CrAg in serum. All participants who tested positive 
for CrAg in serum at baseline consented to be tested for CrAg 
in CSF through LP. Fifty percent (n = 9) of the participants who 
tested CrAg positive in serum also tested positive for CrAg in 
CSF after LP. Furthermore, of 25 individuals who were only 
tested in CSF due to their clinical manifestations compatible 
with CNS compromise, 64% (n = 16) tested negative.
Antiretroviral therapy receipt at baseline was significantly 
lower among individuals who tested positive for CrAg com-
pared with those who tested negative (P = .03). Furthermore, 
the proportion of individuals taking fluconazole for Candida 
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positive for CrAg (P = .04) as was the time since diagnosis of 
HIV, which was significantly lower (P < .01) among those who 
tested positive for CrAg in the cohort (Table 1).
Clinical Features and Outcomes
Fever (64.5% of cases), weight loss (56.8% of cases), and 
headache (50.5% of cases) were the 3 most frequent clinical 
features among the cohort. This finding was consistent in 
both CrAg-positive and CrAg-negative participants. Of all 
the participants, 9.1% (n = 19) had no signs or symptoms at 
baseline and thus were considered asymptomatic (Table  2). 
Thirty-six percent (n = 9 of 25) of the hospitalized individ-
uals had clinical manifestations of CM that was confirmed 













LTFU (n = 5)
Deaths in 1-year (n = 18)










Figure 1. Flowchart of enrollment at human immunodeficiency virus clinics and hospitals in Honduras. *, Hospitalized individuals were only tested in cerebrospinal fluid 
(CSF). CrAg, cryptococcal antigen; LTFU, lost to follow-up.
Table 1. Baseline Characteristics of Patients Enrolled for Cryptococcal 
Antigen Testing in Honduras
Baseline Characteristics
Total 
n = 220 (%)
CrAg Positive 
n = 28 (%)
CrAg Negative 
n = 192 (%) Pa
Age years (median [IQR]) 38 [30–45.5] 36 [28.5–
46.5]
38 [31–45.3] .86
Male sex 140 (63.7) 17 (60.7) 123 (64.0) .83
Urban residence 206 (93.6) 25 (89.3) 181 (94.3) .39
Taking ART 147 (66.8) 10 (35.8) 137 (71.4) <.01
CD4 count cells/mm3 (me-
dian [IQR])
46 [25–72] 40 [23.75–54] 48 [25–72] .20
Time since HIV diagnosis in 
months (median [IQR])
21 [1–111] 1 [1–51] 36 [1–120] <.01
History of previous mycosis 47 (21.4) 5 (17.9) 42 (21.9) .80
Fluconazole prophylaxis 98 (44.5) 7 (25.0) 91 (47.4) .04







Hospitalized participants 25 (11.4) 9 (32.1) 16 (8.3) <.01
Abbreviations: ART, antiretroviral therapy; CrAg, cryptococcal antigen; HIV, human immu-
nodeficiency virus; IQR, interquartile range.
aχ 2, Fisher’s exact test, or Wilcoxon rank-sum test as appropriate to compare CrAg-positive 
and CrAg-negative groups.
Table 2. Baseline Clinical Features of 220 PWH in Honduras by CrAg 
Status
Total n = 220
CrAg Negative 
n = 192 (%)
CrAg Positive 
n = 28 (%) Pa
Clinical Features
 Weight loss 118 (61.5) 17 (60.7) .93
 Fever 117 (60.9) 25 (89.3) <.01
 Headache 93 (48.4) 18 (64.3) .11
 Cough 78 (40.6) 10 (35.7) .62
 Diarrhea 74 (38.5) 7 (25.0) .16
 Oral lesions 56 (29.2) 9 (32.1) .74
 Nausea 54 (28.1) 17 (60.7) <.01
 Wasting syndrome 46 (23.9) 12 (42.9) .03
 Dyspnea 42 (21.9) 6 (21.4) .95
 Mental status impairment 27 (14.1) 11 (39.3) <.01
 Cranial nerve compromise 18 (9.4) 5 (17.9) .09
 Seizures 10 (5.2) 3 (10.7) .25
 Nape rigidity 6 (3.13) 7 (25.9) <.01
Abbreviations: CrAg, cryptococcal antigen; PWH, people with human immunodeficiency 
virus.
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with CM was 40 years (IQR, 33–43), and male sex was pre-
dominant with 66.7% (n = 6) of the cases. Furthermore, 
median CD4 was 40 cells/mm3 (IQR, 28–58 cells/mm3). 
Sixty-six percent (n = 6) of individuals with CM were taking 
ART at the time of the diagnosis.
Eleven percent (n = 25) of study participants died during the 
12-month follow-up period. The proportion of deaths was sig-
nificantly higher among those who tested CrAg positive (25% 
vs 9.4%; P = .01). Thirty-six percent (n = 9 of 25) of the overall 
deaths occurred during the first 90  days. Forty-two percent 
(n = 3) of the 7 overall deaths in the CrAg-positive group oc-
curred during the first 90 days of follow up. Of 9 individuals 
who tested positive in serum but negative in CSF, no deaths 
were reported after a 12-month follow-up period. Furthermore, 
none of these individuals developed CM during the same 
follow-up period.
Among those individuals who received fluconazole-
based therapy for CNS involvement, 57.1% (4 of 7)  died 
during their hospitalization. In contrast, among individ-
uals who received combined therapy with fluconazole and 
amphotericin B deoxycholate, 25.0% (3 of 12)  died during 
their hospitalization.
Individuals who tested positive for CrAg were at a higher 
risk of death after adjusting for sex and use of ART at base-
line (hazard ratio, 2.69; 95% confidence interval, 1.07–6.84) 
(Figure  2). Three percent (n = 5) of the participants in the 
CrAg-negative group were lost to follow up. Loss to follow up 
was not reported in the CrAg-positive group.
DISCUSSION
To our knowledge, this the first study to assess CrAg prevalence 
and outcomes in Central America, demonstrating a high prev-
alence of 12.7% among PWH whose CD4 was ≤100 cells/mm3. 
Although previous models have estimated that the burden of 
cryptococcal disease is high in Latin America [1], these models 
were built in absence of any data from Central America. This 
study allows for updates for the world estimates of cryptococ-
cosis and informs the need for CrAg screening of PWH with 
a CD4 ≤100 cells/mm3 in Central America. Furthermore, this 
study describes the risk of death among individuals tested for 
CrAg during a 12-month follow-up period in an unexplored 
HIV cohort.
The overall prevalence of CrAg among the Honduran cohort 
was 12.7%. This finding is particularly high when compared 
with other African low-income settings where CrAg prevalence 
ranges from 4% to almost 10% [15–17]. Furthermore, when 
gauging the characteristics of those participants who tested 
positive for CrAg, our findings are comparable to reports else-
where [15–17] where young males are more likely to test posi-
tive for CrAg.
Although little is known about the prevalence of cryptococcal 
antigenemia in Central American countries, some reports have 
estimated its prevalence in South American countries. Our 
findings suggest that cryptococcal antigenemia prevalence is 
potentially higher than most of the studies in South America 
[8, 9, 18]. However, testing among these cohorts was performed 
on individuals with CD4  <200 cell/mm3 [7, 8], and thus this 
1.00
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could explain potential differences of cryptococcal antigenemia 
prevalence with our study. Moreover, a Brazilian cohort also 
showed a prevalence of CrAg in CSF of 8.9% [8], comparable to 
our findings where prevalence in CSF was almost 8%. However, 
unlike the Honduran cohort, this study included only inpatient 
participants. Likewise, a recent Argentinian cohort of HIV par-
ticipants with CD4 ≤100 cells/mm3 reported to have a preva-
lence of 8.1% [9], which is also lower than what is reported in 
our study. Thus, our finding suggests that the burden of cryp-
tococcal antigenemia in Central America might be the highest 
or among the highest in Latin America and therefore urges 
the need of CrAg testing among individuals with HIV with 
CD4 ≤100 cells/mm3.
Latin America ranks third in HIV prevalence worldwide 
below Africa and Southeast Asia [19]. Likewise, when as-
sessing the prevalence of CM, Latin America also ranks third 
[1]. However, models that state that the burden of CM is high 
in African countries include several studies performed at this 
region, where CrAg testing is more frequent than in Latin 
America. Therefore, Latin America might have a lower re-
ported burden compared with Africa due to lack of access to 
tools to diagnose this disease or lack of public health programs 
that require testing for this disease. This is why our estimates in 
this study become notable because with a significantly smaller 
number of HIV cases, prevalence of cryptococcal antigenemia 
might be similar [15, 20, 21] or even higher [4, 17, 22–24] 
than in some African countries with a higher burden of HIV. 
Therefore, our findings suggest that actual models of crypto-
coccal infections worldwide might not be accurate when as-
sessing the burden of this disease in Central America.
The proportion of fatalities in our study was 11.4% among 
the whole cohort. A recent report undertaken at a Brazilian 
HIV clinic showed that overall mortality was 27%. However, 
the Brazilian cohort performed CrAg testing in participants 
with CD4  <200 cell/mm3 [8]. Nevertheless, our estimates 
show that CrAg-positive individuals had a higher risk of 
mortality compared with those who tested negative. This 
concurs with what has been reported recently, where the risk 
of death is almost 3 times higher among those individuals 
who tested positive for CrAg [16, 25]. Likewise, this study in 
a South African cohort of PWH with CD4 ≤100 cells/mm3 
reported an overall mortality among CrAg-positive parti-
cipants of 25% after 12  months follow up [16], which was 
the same as our estimate. Furthermore, our results reinforce 
previous findings that mortality is still high among this par-
ticular set of patients even after implementing preemptive 
therapy [16, 25].
Almost 50% of those individuals who tested negative for 
CrAg were taking fluconazole for Candida infection pre-
vention compared with only 25% among those who tested 
positive. These differences could be explained by the fact 
that individuals who were under fluconazole therapy in the 
CrAg-negative group had also a higher median amount of 
time taking ART. Recent findings show that enhanced prophy-
laxis with fluconazole reduces the frequency of cryptococcosis 
among PWH [26]. Although prophylaxis for cryptococcal dis-
ease is not recommended in contexts in which the prevalence 
is low [27], this could potentially be reconsidered in the set-
ting of a low-resource country where the prevalence of CrAg 
is potentially high, which is consistent with our study that re-
ports one of the highest CrAg prevalence estimates in Latin 
American and even worldwide.
Overall, this study reinforces the need of implementing CrAg 
screening in Central America to determine the real burden of 
cryptococcal antigenemia among PWH. Honduras currently 
does not require CrAg testing as screening when HIV is newly 
diagnosed or among PWH with CD4 ≤100 cells/mm3 as recom-
mended by the WHO [13]. Furthermore, implementing CrAg 
screening has proven to be cost-effective in low-resource set-
tings [2, 5, 6] and should therefore be an option in Honduras, 
taking into account this study where the prevalence of CrAg 
positivity appears to be high.
One of the major limitations associated to our mortality 
analysis is not being able to determine the amount of time 
individuals in the cohort were taking ART during the study 
period or previously limited our analysis. Furthermore, when 
assessing mortality, we were not able to determine the causes 
of death among the cohort. The methodology of testing in-
dividuals either in serum or CSF depending on clinical 
manifestations at presentation might have led to bias in the 
prevalence of CrAg in serum but not the overall CrAg preva-
lence. Finally, we were not able to determine (1) the compli-
ance to ART among participants, (2) the rate of abandoning 
ART among those who had being taking ART for a longer 
time, and (3) how the result on CrAg testing would be affected 
by this situation.
CONCLUSIONS
In conclusion, our study findings suggest there is a high prev-
alence of cryptococcal antigenemia among PWH in Central 
American, even when compared with studies in Africa where 
the HIV burden is higher. Systematic screening for CrAg should 
be considered in the region based on our results to address this 
major public health concern.
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